Table 2

Preference and feasibility outcomes associated with the use of rapid multiplexed STI diagnostic devices

Author, yearPreference/feasibility outcomeTest typeSTI(s) testedResult
Pai et al, 201419Preference for multiplexed testingIMTHIV, HBV, HCV, syphilis106/109=97.2% preference rate
Pai et al, 2014*19Preference for multiplexed testingIMT226/374=60.2% preference rate
Pant Pai et al, 201921Preference for multiplexed testingIMTHIV, HBV, HCV, TV73.0% preference rate
Pant Pai et al, 201921Satisfaction with multiplexed testingIMT453/491=92.0% satisfaction rate
Pai et al, 201419Satisfaction with multiplexed testingIMTHIV, HBV, HCV, syphilis373/375=99.5% satisfaction rate
Menzato et al, 201818Acceptance of multiplexed testingIMTHIV898/898=100.0% acceptance rate
Pant Pai et al, 201921Acceptance of multiplexed testingIMTHIV, HBV, HCV, TV510/510=100.0% acceptance rate
Pai et al, 201419Recommend multiplexed testing to othersIMTHIV, HBV, HCV, syphilis108/109=99.1% recommendation rate
Pai et al, 2014*19Recommend multiplexed testing to othersIMTHIV, HBV, HCV, syphilis125/375=33.0% recommendation rate
Pant Pai et al, 201921CompletionIMTHIV, HBV, HCV, TV466/510=91.6% completion rate
Pai et al, 201419CompletionIMTHIV, HBV, HCV, syphilis109/118=92.4% completion rate
Pai et al, 2014*19CompletionIMTHIV, HBV, HCV, syphilis323/375=86.1% completion rate

  • *Study conducted in Canadian and Indian populations.

  • HBV, hepatitis B virus; HCV, hepatitis C virus; IMT, immunochromatographic test; STI, sexually transmitted infection; TV, Trichomonas vaginalis.